Quinazolinone PARP14 Inhibitors for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new medications that can effectively treat cancers and inflammatory conditions characterized by abnormal expression or activity of PARP14, as current therapies are inadequate in addressing these issues.
Innovation Solution
Development of a compound of Formula I, or its pharmaceutically acceptable salt, which inhibits PARP14 activity, decreases IL-10 production, and is used to treat diseases with overexpression or increased activity of PARP14, including cancer and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat cancers with abnormal PARP14 expression, then treatment is provided, but the treatment is inadequate and does not effectively address the underlying mechanism
Solution Approach 1:
The patent introduces PARP14 as a specific intermediary target between the general PARP family and cancer treatment. By developing compounds that selectively inhibit PARP14 rather than broadly inhibiting all PARPs, the invention achieves mechanism-specific targeting while maintaining treatment effectiveness. The quinazolinone compounds act as intermediaries that specifically bind to and inhibit PARP14 enzymatic activity, thereby resolving the contradiction between general treatment approach and specific mechanism targeting.
Solution Approach 2:
The patent changes the key parameter from general PARP inhibition to specific PARP14 inhibition. By modifying the selectivity parameter of the inhibitor compounds, the invention achieves both reliable treatment effectiveness and adaptability to the specific PARP14-overexpressing cancer mechanism. The quinazolinone compounds exhibit selective binding affinity for PARP14, changing the inhibition specificity parameter to resolve the technical contradiction.
2Reliability
If PARP14 activity is inhibited to treat cancer, then therapeutic benefit is achieved, but IL-10 production is decreased which may have immunological consequences
Solution Approach 1:
The patent applies partial action by selectively inhibiting PARP14 enzymatic activity without completely blocking all PARP family functions. The quinazolinone compounds are designed to achieve sufficient PARP14 inhibition for cancer treatment efficacy while allowing other PARP members to maintain their normal functions, including those involved in IL-10 production regulation. This partial specificity approach resolves the contradiction between achieving therapeutic benefit and avoiding harmful side effects.
3Measurement precision
If new medications targeting PARP14 are developed, then treatment specificity is improved, but drug development complexity and time increase
Solution Approach 1:
The patent achieves universality by developing a quinazolinone scaffold that can be systematically optimized for PARP14 specificity. The core molecular framework provides a universal platform that allows for structured modification to achieve precise target binding. This multi-functional approach enables the same scaffold to be adapted for different PARP14 inhibitor variants, reducing overall development time while maintaining high target specificity through systematic structure-activity relationship studies.
Data Source
AI summary
The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.